Core Viewpoint - The company, Zhejiang Shengda Biological Pharmaceutical Co., Ltd., is undergoing a change in its auditing firm for the 2025 fiscal year, transitioning from Tianjian Accounting Firm to RSM China (致同会计师事务所) due to the need for fresh auditing perspectives and compliance with regulations [4][11]. Group 1: Company Overview - The company is identified by the stock code 603079 and is referred to as Shengda Biological [3]. - The company has confirmed that there are no changes in its controlling shareholders or actual controllers during the reporting period [2]. Group 2: Financial Data - The company raised a total of RMB 267.61 million through a stock issuance, with a net amount of RMB 261.42 million after deducting issuance costs [48]. - The average selling price of the company's main products, vitamins, increased by 45.78% year-on-year and 4.98% quarter-on-quarter in the second quarter [57]. Group 3: Audit Firm Change - The new auditing firm, RSM China, has been selected based on its professional competence and experience in providing auditing services to listed companies [11][12]. - The previous auditing firm, Tianjian, provided standard unqualified opinions for the 2024 financial report [11]. - The change in auditing firms was communicated to both the outgoing and incoming firms, with no objections raised [4][11]. Group 4: Shareholder Meeting - The third extraordinary general meeting of shareholders is scheduled for September 10, 2025, to discuss the appointment of the new auditing firm [15][14]. - The voting for the shareholder meeting will be conducted through both on-site and online methods [15][16]. Group 5: Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and managed according to regulatory requirements [50][51]. - There were no instances of using idle raised funds for temporary working capital during the reporting period [55].